Skip to main content
Premium Trial:

Request an Annual Quote

HTG Molecular, Firalis Ink Deal for RA Theranostic Technology

NEW YORK (GenomeWeb) – French biotechnology firm Firalis has signed a non-exclusive agreement to obtain HTG Molecular Diagnostics' technology and components to support its commercialization of a next-generation sequencing-based rheumatoid arthritis (RA) theranostic assay.

Called BIOPRED — short for biomarker assay to predict treatment response — Firalis' assay is designed to predict how RA patients will respond to anti‑TNF-alpha therapy. In 2016, the companies partnered to adapt the assay for use on HTG's EdgeSeq platform.

Under the newest deal, HTG will supply assay components to Firalis, which will manufacture, obtain applicable regulatory approvals for, and sell the BIOPRED assay as kits and Firalis-based services for research and diagnostic applications worldwide. All kits and services will be automated on EdgeSeq systems purchased directly from HTG by end users.

Additional terms were not disclosed.

"Firalis was one of the first adopters of the HTG EdgeSeq system in Europe, and we are pleased to support them in the next steps in this personalized medicine initiative," HTG CEO TJ Johnson said in a statement. "Strategic supply and non‑exclusive technology out‑licensing is another way to further our business objectives of market recognition and expansion and revenue growth."

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.